A Phase 3 interventional study of Atorvastatin 20 mg / Fenofibrate 160 mg in fixed dose and Atorvastatin (Lipitor ®) in Dyslipidemia Associated With Type II Diabetes Mellitus, sponsored by Laboratorios Silanes S.A. de C.V.. Status unknown at 1 site in Mexico. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-02.
Sponsored by Laboratorios Silanes S.A. de C.V. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies testing atorvastatin in Dyslipidemias — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Dyslipidemias.
Among the 47 studies testing atorvastatin in Dyslipidemias, this one is the 33rd largest by planned enrollment, is one of 2 that started in 2022, is one of 12 in phase 3, and was the 43rd registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →1 of the 47 studies testing atorvastatin in Dyslipidemias is open now, in 1 country. Recruiting first, the newest first:
Yonsei University · Sites in Korea, Republic of
Ages 19–80
By country, each count listing its studies:
Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 78 is below the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 165 across the 47 interventional studies. Of the 42 that completed or were terminated, 11 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 47 have an industry lead sponsor. The 10 most frequent:
Laboratorios Silanes S.A. de C.V. is the lead sponsor of 45 studies on the registry; 1 is open to participants now.
Laboratorios Silanes S.A. de C.V. has 3 studies filed under Dyslipidemias — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 47 studies testing atorvastatin in Dyslipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Phase IIIb, randomized, longitudinal, prospective, multicenter study to evaluate the efficacy and safety of the fixed-dose combination atorvastatin / fenofibrate versus atorvastatin on the lipid profile of patients with type 2 diabetes and dyslipidemia.
To assess the efficacy and safety of the fixed-dose combination atorvastatin / fenofibrate versus atorvastatin on the lipid profile of patients with type 2 diabetes and dyslipidemia. Assessing the magnitude of change in lipid profile numbers. And describing the effect on anthropometric, biochemical and clinical indicators, as well as events and adverse reactions that may occur. In patients diagnosed with type 2 diabetes and dyslipidemia (triglycerides> 150 mg / dl, LDL (Low density lipoprotein) cholesterol> 100 mg / dl) and who require pharmacological treatment for lipid control.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group A: Atorvastatin / Fenofibrate in fixed dose Pharmaceutical Form: Tablets Dosage: 20 mg /160 mg Adminstration way: Oral
Drug: Atorvastatin 20 mg / Fenofibrate 160 mg in fixed dose
Group B: Atorvastatin (Lipitor ®) Pharmaceutical Form: Tablets Dosage: 20 mg Adminstration wat: Oral
Drug: Atorvastatin (Lipitor ®)
Drug page: Atorvastatin
1 tablet once a day, 20 mg /160 mg, Orally
Also known as: ATV / FENO
1 tablet once a day, 20 mg, Orally
Also known as: ATV (Lipitor ®)
Magnitude of change in lipid profile figures.
To assess the magnitude of change in lipid profile figures (Lp \[a\], LDL, and triglycerides) at 2 and 4 months with respect to their baseline measurement and between treatment groups.
Time frame: Baseline, 2 and 4 months.
Proportion of subjects achieving triglyceride levels <150 mg /dL.
Describe the proportion of subjects who achieved triglyceride levels \<150 mg / dL at the end of treatment.
Time frame: 4 months
Describe the proportion of subjects who reduced levels of LDL cholesterol
Describe the proportion of subjects who reduced levels of LDL cholesterol, under 30% compare to the baseline value.
Time frame: Baseline and 4 months.
Impact on anthropometric indicators (Weight)
Describe changes in weight (kg) measurements from baseline to the end of the study (4 months).
Time frame: Baseline and 4 Months
Impact on anthropometric indicators body mass index (BMI)
Describe changes in BMI (kg/m2) from baseline to the end of the study (4 months)
Time frame: Baseline and 4 months
Impact on anthropometric indicators (Waist circumference)
Describe changes in waist circumference (cm) from baseline to the end of the study (4 months).
Time frame: Baseline and 4 months
Impact on liver function with aspartate aminotransferas (AST)
Describe the changes in AST (mg/dL) concentration, between baseline and the end of the study.
Time frame: Baseline and 4 months
Impact on liver function with Alanine Aminotransferase (ALT)
Describe the changes in ALT (mg/dL) concentration, between baseline and the end of the study.
Time frame: Baseline and 4 months
Impact on Glycosylated hemoglobin (HbA1c)
Describe the changes in HbA1c percentage from baseline to the end of the study (4 months).
Time frame: Baseline and 4 months
Impact on glucose levels
Describe the changes in glucose levels (mg/dL) from baseline to the end of the study (4 months).
Time frame: Baseline and 4 months
Impact on Blood pressure
Describe the changes in blood pressure (mm Hg) from baseline to the end of the study (4 months). impact on clinical indicators (Blood pressure, Heart rate, Respiratory rate).
Time frame: Baseline and 4 months
Impact on heart rate
Describe the changes in heart rate (beats per minute) from baseline to the end of the study (4 months).
Time frame: Baseline and 4 months
Impact on respiratory rate
Describe the changes in respiratory rate (Pulses per minute) from baseline to the end of the study (4 months).
Time frame: Baseline and 4 months
Events and adverse reactions presented.
Proportion of events and adverse reactions presented during 4 months of treatment.
Time frame: 4 months
Plan to share: No
Started Feb 2022 (actual). Primary completion is estimated for May 2022, 3 months after the start.
Of 52 industry-sponsored phase 3 interventional studies under Dyslipidemias, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's planned 3 months is below that.
Counting every sponsor, half of 62 studies reached it within 22 months; a quarter within 12 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atorvastatin
Laboratorios Silanes S.A. de C.V. →